Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis bluebird bio Inc. BLUEV


Primary Symbol: BLUE

bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.


Opinion & Analysis (NDAQ:BLUE)

    Coverage Initiated on Cancer Vaccine Firm

    Streetwise Reports March 11, 2019

    Risk Versus Reward: The Value of Cell Therapy for Patients and Investors

    Streetwise Reports April 25, 2018

    Partnerships propel Stellar Biotechnologies' vaccine technology

    The Life Sciences Report June 22, 2016

    CAR T-cell therapeutics: Alan Leong of BioWatch looks beyond the buzz for solid early-stage plays

    Gail Dutton September 10, 2015

    Buy biotech when there's blood on the street: Pontifax's Ran Nussbaum

    George S. Mack September 3, 2015

    Zacks' Jason Napodano is not focused on a biotech bubble

    George S. Mack July 9, 2015